News
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...
Novo Nordisk stock (ticker: NVO) fell after the drugmaker unexpectedly cuts its full-year guidance, citing lower sales ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Compounding pharmacies are crimping sales of Novo Nordisk’s obesity drug Wegovy by making what are essentially copies of the ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk on Tuesday cut its full-year sales and operating profit forecasts for ...
July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar ...
Jared Holz, Mizuho health care equity strategist, joins 'Money Movers' to discuss Novo Nordisk sinking on guidance cut and ...
Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback